Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) saw an uptick in trading volume on Friday . 340,838 shares changed hands during trading, an increase of 22% from the previous session's volume of 279,332 shares.The stock last traded at $15.35 and had previously closed at $12.34.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. Jefferies Financial Group downgraded Mesoblast from a "buy" rating to a "hold" rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Report on MESO
Mesoblast Trading Up 27.5%
The stock has a 50 day moving average price of $11.23 and a 200-day moving average price of $13.62. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Lazari Capital Management Inc. raised its position in Mesoblast by 2.2% during the 2nd quarter. Lazari Capital Management Inc. now owns 46,471 shares of the company's stock valued at $506,000 after purchasing an additional 1,003 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of Mesoblast by 41.1% in the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after buying an additional 1,891 shares during the last quarter. Barclays PLC purchased a new stake in shares of Mesoblast in the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. purchased a new stake in shares of Mesoblast in the 4th quarter worth approximately $50,000. Finally, BNP Paribas Financial Markets lifted its position in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after acquiring an additional 2,597 shares in the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
